IPCA Laboratories Limited
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- ₹173.43 billion
- Book Value:
- Revenue TTM:
- ₹60.22 billion
- Operating Margin TTM:
- Gross Profit TTM:
- ₹36.23 billion
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
IPCA Laboratories Limited had its IPO on under the ticker symbol IPCALAB.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. IPCA Laboratories Limited has a staff strength of 15,155 employees.
Shares of IPCA Laboratories Limited opened at ₹682.45 at the start of the last trading session i.e. 2023-05-28.
The stocks traded within a range of ₹677.55 - ₹685.9, and closed at ₹684.45.
This is a +0.4% increase from the previous day's closing price.
A total volume of 171,129 shares were traded at the close of the day’s session.
In the last one week, shares of IPCA Laboratories Limited have increased by +1.38%.
IPCA Laboratories Limited's Key Ratios
IPCA Laboratories Limited has a market cap of ₹173.43 billion, indicating a price to book ratio of 3.7935 and a price to sales ratio of 3.7514.
In the last 12-months IPCA Laboratories Limited’s revenue was ₹60.22 billion with a gross profit of ₹36.23 billion and an EBITDA of ₹9.27 billion. The EBITDA ratio measures IPCA Laboratories Limited's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, IPCA Laboratories Limited’s operating margin was 11.53% while its return on assets stood at 14.04% with a return of equity of 25.46%.
In Q4, IPCA Laboratories Limited’s quarterly earnings growth was a negative -45.2% while revenue growth was a positive 8.1%.
IPCA Laboratories Limited’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at ₹20.71 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into IPCA Laboratories Limited’s profitability.
IPCA Laboratories Limited stock is trading at a EV to sales ratio of 3.6275 and a EV to EBITDA ratio of 18.5539. Its price to sales ratio in the trailing 12-months stood at 3.7514.
IPCA Laboratories Limited stock pays annual dividends of ₹4 per share, indicating a yield of 0.59% and a payout ratio of 25.7%.
Balance sheet and cash flow metrics
- Total Assets
- ₹78.98 billion
- Total Liabilities
- ₹13.85 billion
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
IPCA Laboratories Limited ended 2023 with ₹78.98 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹78.98 billion while shareholder equity stood at ₹57.78 billion.
IPCA Laboratories Limited ended 2023 with ₹0 in deferred long-term liabilities, ₹13.85 billion in other current liabilities, 253700000.00 in common stock, ₹57.53 billion in retained earnings and ₹541.60 million in goodwill. Its cash balance stood at ₹3.87 billion and cash and short-term investments were ₹14.57 billion. The company’s total short-term debt was ₹0 while long-term debt stood at ₹4.33 billion.
IPCA Laboratories Limited’s total current assets stands at ₹45.54 billion while long-term investments were ₹0 and short-term investments were ₹2.65 billion. Its net receivables were ₹11.03 billion compared to accounts payable of ₹5.76 billion and inventory worth ₹18.23 billion.
In 2023, IPCA Laboratories Limited's operating cash flow was ₹0 while its capital expenditure stood at ₹0.
Comparatively, IPCA Laboratories Limited paid ₹0.26 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
IPCA Laboratories Limited stock is currently trading at ₹684.45 per share. It touched a 52-week high of ₹1028.7404 and a 52-week low of ₹1028.7404. Analysts tracking the stock have a 12-month average target price of ₹.
Its 50-day moving average was ₹755.11 and 200-day moving average was ₹845.76 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 4666.3% of the company’s stock are held by insiders while 4068.2% are held by institutions.
Frequently Asked Questions About IPCA Laboratories Limited
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Ipca Laboratories Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India. It offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. The company provides generic and branded formulations in the therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, dermatology, diabetology, gastroenterology, haematology, neurology, ophthalmology, rheumatology, and urology, as well as respiratory, psychiatry, probiotics, orthopedics, oral anti diabetes drug, nutraceuticals, NSAIDs, neuropathic pain, malaria, infectious diseases, immunosuppressant, hepatoprotectives, helminthics, fever, and emollients/protectives. It exports its products to approximately 100 countries worldwide. The company was incorporated in 1949 and is based in Mumbai, India.